InsidersTradesSigma
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Browse the detailed record of transactions filed by Doyle John Brendan. Director active across 1 company, notably Cognition Therapeutics INC. Cumulatively, 11 reports have been recorded. Split: 1 buy · 0 sell. Total volume traded: €10k. History available since 1 May 2023. The latest transaction was disclosed on 16 April 2026 (Acquisition). Regulator: SEC (Form 4). All data is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
11 of 11 declarations
Doyle John Brendan is Chief Financial Officer at Cognition Therapeutics INC (XNAS). The record shows 11 filings, and across the 11 sampled filings, activity runs from 2023-05-03 to 2026-04-20, with EUR 9590 of buys and EUR 0 of sells, and the most common transaction nature is Attribution.